Nanobiotix Stock Forecast, Price & News

Nanobiotix (NASDAQ:NBTX) Frequently Asked Questions

Is Nanobiotix a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nanobiotix in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nanobiotix stock.
View analyst ratings for Nanobiotix or view top-rated stocks.

Are investors shorting Nanobiotix?

Nanobiotix saw a drop in short interest in December. As of December 15th, there was short interest totaling 1,200 shares, a drop of 58.6% from the November 30th total of 2,900 shares. Based on an average daily volume of 4,400 shares, the days-to-cover ratio is presently 0.3 days.
View Nanobiotix's Short Interest.

When is Nanobiotix's next earnings date?

Nanobiotix is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Nanobiotix.

Who are Nanobiotix's key executives?

Nanobiotix's management team includes the following people:

• Mr. Laurent Levy, Co-Founder, Pres of the Exec. Board & CEO (Age 48, Pay $612.35k)
• Ms. Anne-Juliette Hermant M.A., Chief People Officer & Member of Exec. Board (Age 47, Pay $358.08k)
• Prof. Para Prasad Ph.D., Co-Founder and Member of Scientific Board (Age 76)
• Mr. Earl J. Bergey Ph.d., Co-Founder (Age 66)
• Mr. Bart Van Rhijn, CFO & Member of Exec. Board
• Mr. Alain Dostie, Chief Operating Officer
• Ms. Kathryn M. McNeil, Sr. VP of Investor Relations (Age 46)
• Mr. Brandon Owens, VP of Strategic Marketing & Corp. Communication
• Ms. Elsa Borghi, Head of Innovation & Drug Discovery
• Ms. Sarah Gaubert, Head of Communication & Public Affairs Department

Who are some of Nanobiotix's key competitors?

Some companies that are related to Nanobiotix include Amarin (AMRN), Amphastar Pharmaceuticals (AMPH), Enanta Pharmaceuticals (ENTA), NGM Biopharmaceuticals (NGM), Innoviva (INVA), Avid Bioservices (CDMO), Madrigal Pharmaceuticals (MDGL), Keros Therapeutics (KROS), MorphoSys (MOR), ADC Therapeutics (ADCT), PureTech Health (PRTC), Vectura Group (VEGPF), ImmunoGen (IMGN), Procaps Group S.A (PROC) and Vaxxinity (VAXX).
View all of NBTX's competitors.

When did Nanobiotix IPO?

(NBTX) raised $95 million in an IPO on Friday, December 11th 2020. The company issued 6,500,000 shares at a price of $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO.

What is Nanobiotix's stock symbol?

Nanobiotix trades on the NASDAQ under the ticker symbol "NBTX."

How do I buy shares of Nanobiotix?

Shares of NBTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nanobiotix's stock price today?

One share of NBTX stock can currently be purchased for approximately $8.98.

How much money does Nanobiotix make?

Nanobiotix has a market capitalization of $312.74 million and generates $2.87 million in revenue each year.

How many employees does Nanobiotix have?

Nanobiotix employs 89 workers across the globe.

What is Nanobiotix's official website?

The official website for Nanobiotix is www.nanobiotix.com.